# Avedro

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avedro

- Industry: Medical Devices & Equipment
- Headquarters: Waltham, US
- Website: www.avedro.com
- Total disclosed funding: $101M
- Latest round: Series F (May 2, 2018)
- Investors on record: 15

## About

Avedro, Inc. is a biotechnology company specializing in advanced ocular therapies that aim to treat corneal diseases, primarily focusing on the innovative treatment of keratoconus and presbyopia.Founded in 2007, Avedro, Inc. is based in Waltham, US. The company develops and commercializes products for the treatment of corneal diseases. Kenneth Crockett is the founder, who has a history in the medical device industry. Avedro completed its most recent funding round, an IPO, on February 14, 2019, raising USD 70.00 mn, bringing the total amount raised to USD 70.00 mn. The company has engaged in 14 total deals.Avedro specializes in developing innovative therapies for chronic corneal conditions such as keratoconus and presbyopia. Their product portfolio includes advanced cross-linking procedures aimed at strengthening corneal tissue and improving vision outcomes in patients with these conditions. Avedro's products are marketed to ophthalmologists and eye care professionals globally, including regions in the United States and Europe, providing comprehensive solutions for effective vision management.In 2018, Avedro reported a revenue of USD 27.67 mn, with an EBITDA of USD -20.57 mn. The company's revenue is primarily generated through the sale of its proprietary ocular therapies to hospitals and healthcare providers, focusing on enhancing surgical results and patient care.Avedro plans to expand its product offerings by introducing new therapies targeting presbyopia, with anticipated launches in the next 12 to 18 months. The company aims to penetrate new markets in Asia and Europe by late 2020, leveraging its recent IPO funding of USD 70.00 mn to support these initiatives and enhance product development and market entry strategies.

## Funding rounds

- Series F, May 2, 2018, $25M — InterWest Partners, OrbiMed Advisors, Lilly Asia Ventures, HealthQuest Capital
- Series D, Mar 5, 2013, $42M — Abingworth, Flagship Pioneering, Prism Venture Management, SCP Partners, De Novo Ventures, Echelon Ventures, Aperture Venture Partners, Borealis Ventures, Third Point
- Series C, Feb 17, 2012, $0.5M — SCP Vitalife Partners, De Novo Ventures, One Liberty Ventures, Borealis Ventures
- Series C, Jul 7, 2011, $26M — Flagship Pioneering, Prism Venture Management, SCP Partners, De Novo Ventures, Echelon Ventures, Aperture Venture Partners, Borealis Ventures
- Series A, Feb 11, 2008, $8M — Prism Venture Management, Echelon Ventures, Borealis Ventures

## Investors

- Prism Venture Management (https://capitalatlas.ai/funds/prism-venture-management) — Series A, Series C, Series D
- Echelon Ventures (https://capitalatlas.ai/funds/echelon-ventures) — Series A, Series C, Series D
- Borealis Ventures (https://capitalatlas.ai/funds/borealis-ventures) — Series A, Series C, Series D
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series C, Series D
- SCP Partners (https://capitalatlas.ai/funds/scp-partners) — Series C, Series D
- De Novo Ventures (https://capitalatlas.ai/funds/de-novo-ventures) — Series C, Series D
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series C, Series D
- SCP Vitalife Partners (https://capitalatlas.ai/funds/scp-vitalife-partners) — Series C
- One Liberty Ventures (https://capitalatlas.ai/funds/one-liberty-ventures) — Series C
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series D
- Third Point (https://capitalatlas.ai/funds/third-point) — Series D
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series F
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series F
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series F
- HealthQuest Capital (https://capitalatlas.ai/funds/healthquest-capital) — Series F